Overview

Regression of Myocardial Steatosis by Nebivolol

Status:
Completed
Trial end date:
2013-02-11
Target enrollment:
Participant gender:
Summary
Within large number of patients with obesity, it is crucial to determine who is at the greatest risk for development of chronic heart disease. The investigators previous studies suggest that an excessive accumulation of fat in heart cells precedes the development of obesity-related pathologies and may serve as a biomarker of heart disease in high-risk population. Until now, the evaluation of fat in the human heart was possible postmortem or by biopsy. The investigators novel magnetic resonance spectroscopy technique enables the quantification of intracellular lipid content non-invasively and repeatedly in humans in vivo. It could be used to better screen and treat obese patients at risk for the development of metabolic disease. The investigators hypothesize that in obese humans with elevated myocardial triglycerides, treatment with Nebivolol will reduce myocardial fat and will improve heart function.
Phase:
Early Phase 1
Details
Lead Sponsor:
Cedars-Sinai Medical Center
Lidia Szczepaniak
Collaborator:
Forest Laboratories
Treatments:
Nebivolol